DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Thursday morning. The firm issued a hold rating on the stock.

Several other research firms have also recently issued reports on DBVT. HC Wainwright upped their price objective on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Price Performance

DBVT stock traded up $0.03 during trading on Thursday, hitting $0.59. 62,115 shares of the stock traded hands, compared to its average volume of 229,916. The stock has a market cap of $56.92 million, a price-to-earnings ratio of -0.65 and a beta of 0.66. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $2.14. The firm’s 50 day moving average is $0.73 and its two-hundred day moving average is $0.89.

Shares of DBV Technologies are scheduled to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.